ARS Pharmaceuticals (SPRY) Enterprise Value (2021 - 2025)
Historic Enterprise Value for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$288.2 million.
- ARS Pharmaceuticals' Enterprise Value fell 4084.81% to -$288.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$288.2 million, marking a year-over-year decrease of 4084.81%. This contributed to the annual value of -$314.0 million for FY2024, which is 3751.18% down from last year.
- Latest data reveals that ARS Pharmaceuticals reported Enterprise Value of -$288.2 million as of Q3 2025, which was down 4084.81% from -$240.1 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Enterprise Value ranged from a high of -$60.1 million in Q4 2021 and a low of -$374.2 million during Q1 2021
- In the last 5 years, ARS Pharmaceuticals' Enterprise Value had a median value of -$258.0 million in 2022 and averaged -$257.9 million.
- Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Enterprise Value was 3216.37% (2022), while the steepest drop was 35682.2% (2022).
- ARS Pharmaceuticals' Enterprise Value (Quarter) stood at -$60.1 million in 2021, then crashed by 356.82% to -$274.4 million in 2022, then increased by 16.77% to -$228.4 million in 2023, then plummeted by 37.51% to -$314.0 million in 2024, then increased by 8.22% to -$288.2 million in 2025.
- Its Enterprise Value was -$288.2 million in Q3 2025, compared to -$240.1 million in Q2 2025 and -$275.7 million in Q1 2025.